Publications by authors named "Jordyn Paige Higgins"
Objective: The aim of this study was to characterize the safety of programmed death 1 inhibitors in patients with preexisting autoimmune disease.
Methods: A medical records review study was conducted on adults with solid tumor malignancies who received ≥1 dose of pembrolizumab or nivolumab at Emory Healthcare from September 4, 2014 until December 31, 2019. All autoimmune patients were included (n = 77), whereas the nonautoimmune patients were randomized and the first 156 patients were included in a 2:1 ratio to autoimmune patients.